Status:
COMPLETED
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
Lead Sponsor:
Janssen Cilag S.A.S.
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine p...
Eligibility Criteria
Inclusion
- Participant with a confirmed diagnosis of Psoriatic Arthritis (PsA) according to the dermatological and/or rheumatologic routine practice, using different diagnosis tools, example, the Classification criteria for Psoriatic Arthritis (CASPAR), or others
- Participant must be starting ustekinumab for PsA according to the local labelling, as a first (biological naïve participant), or second line (biological experienced participants) of bDMARD therapy: First line bDMARD therapy: The first line therapy includes all bio-naïve participants who start their ustekinumab as their first biologic treatment at the study start (within a maximum 1-month window after the baseline visit); Second line bDMARD therapy: The second line therapy includes participants who initiated ustekinumab as their second biologic therapy at the study start (within a maximum 1-month window after the baseline visit)
- Participant for which the ustekinumab treatment has been decided by the investigator prior to and independently of the participant's inclusion into the study
- Participant for which the first administration of the ustekinumab treatment will occur within the 4-week period from inclusion assessment
- Participant has signed an informed consent form
Exclusion
- Participant starting ustekinumab as a third or further line of bDMARD therapy
- Already ustekinumab-experienced participants
- Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within at least 30 days before the start of the study or more according to the half-life of the investigational drug
- Participant has refused to participate in the study or unable to give his consent
Key Trial Info
Start Date :
April 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 7 2020
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT03336281
Start Date
April 25 2017
End Date
April 7 2020
Last Update
February 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Edouard Herriot
Lyon, France, 69437